Bright Minds Biosciences, Inc. announced on January 7, 2025, the appointment of Stephen D. Collins, M.D., Ph.D., as its new Chief Medical Officer (CMO), effective immediately. Dr. Collins brings extensive drug development and clinical expertise, particularly in the field of epilepsy.
Prior to joining Bright Minds, Dr. Collins served as CEO of Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, and held leadership roles at Neurotherapeutics Pharma and Ovation Pharmaceuticals, which was acquired by Lundbeck A/S for US $963 million. At Ovation, he was instrumental in developing and approving three anti-convulsant therapies, including Sabril and Frisium.
Ian McDonald, CEO and Co-founder of Bright Minds Biosciences, stated that Dr. Collins's experience in advancing novel therapeutics in the CNS space aligns with the company's mission to develop next-generation serotonin drugs. Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO but will continue to serve in an advisory capacity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.